首页> 中文期刊> 《中外医疗 》 >补肾降压方治疗原发性高血压的可行性及安全性研究

补肾降压方治疗原发性高血压的可行性及安全性研究

             

摘要

Objective To evaluate clinical efficacy of antihypertensive kidney treatment in elderly hypertensive. Methods 151 cas-es of patients from May 2012 to Nov 2014 in our hospital were randomly divided into two groups. For 76 cases in the observation group, was chosed to antihypertensive medicine kidney treatment;for 75 cases in the control group, was chosed to Western conven-tional therapy. Observed and compared the clinical efficacy, and changes of each indexs of the two groups of patients after treat-ment. Results Excellent clinical efficacy in the study group was 94.7%, and the control group was 82.7%. Difference in superior clinical efficacy rate of the two groups was statistically significant (P<0.05). Conclusion The clinical efficacy of antihypertensive Kidney Treatment of essential hypertension is good, it can significantly reduce plasma aldosterone levels in patients, and has fewer side effects, so it deserved to be in clinical practice.%目的:评价补肾降压方治疗老年原发性高血压的临床疗效。方法整群选取2012年5月-2014年11月该院收治的老年原发性高血压患者151例,随机分为两组,其中观察组76例,选用中药补肾降压方进行治疗,对照组75例,选用西医常规疗法进行处理,观察并比较两组患者临床疗效以及各指标变化。结果观察组临床疗效优良率为94.7%,对照组为82.7%,两组患者临床疗效优良率比较差异有统计学意义(P<0.05)。结论补肾降压方治疗老年原发性高血压的临床疗效好,能明显降低患者血浆醛固酮水平,不良反应较少,值得在临床上予以推广。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号